APA (7th ed.) Citation

J, P., B, T., A, D. A., E, M., J, D. l. T., M, N., . . . J, O. (2019). Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: Data at 48 weeks. Infectious diseases (London, England), 51(9), 691. https://doi.org/10.1080/23744235.2019.1637536

Chicago Style (17th ed.) Citation

J, Pérez-Stachowski, et al. "Efficacy and Safety of the Switch of Triumeq® to Generic (abacavir + lamivudine) + Tivicay®: Data at 48 weeks." Infectious Diseases (London, England) 51, no. 9 (2019): 691. https://doi.org/10.1080/23744235.2019.1637536.

MLA (9th ed.) Citation

J, Pérez-Stachowski, et al. "Efficacy and Safety of the Switch of Triumeq® to Generic (abacavir + lamivudine) + Tivicay®: Data at 48 weeks." Infectious Diseases (London, England), vol. 51, no. 9, 2019, p. 691, https://doi.org/10.1080/23744235.2019.1637536.